Get the Stockscreener App
0.8967
2.01%
0.0177
After Hours:
.90
0.0033
+0.37%
Compass Therapeutics Inc stock is traded at $0.8967, with a volume of 3.33M.
It is up +2.01% in the last 24 hours and down -51.53% over the past month.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
See More
Previous Close:
$0.879
Open:
$0.86
24h Volume:
3.33M
Relative Volume:
0.45
Market Cap:
$161.48M
Revenue:
$850.00K
Net Income/Loss:
$-68.17M
P/E Ratio:
-2.1786
EPS:
-0.4116
Net Cash Flow:
$-53.29M
1W Performance:
-8.82%
1M Performance:
-51.53%
6M Performance:
-84.67%
1Y Performance:
-81.20%
1-Day Range:
$0.8504
$0.9046
1-Week Range:
$0.8217
$0.99
52-Week Range:
$0.8217
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
0.8967 | 161.48M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-01-26 | Resumed | Ladenburg Thalmann | Buy |
| Apr-28-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-13-26 | Initiated | Craig Hallum | Buy |
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Top insider buys and sells disclosed on Friday - Investing.com
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com - Investing.com Australia
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com - Investing.com Nigeria
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com - Investing.com South Africa
Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares - Investing.com
Form 4 Compass Therapeutics, Inc. For: 2 October - Investing.com India
Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares By Investing.com - Investing.com Canada
Compass Therapeutics CAO Neil Lerner Purchases 20,000 Shares in Open Market Transaction - Kalkine Media
At $0.92 a share, Compass Therapeutics (CMPX) accounting chief buys 20,000 shares. - Stock Titan
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares - GuruFocus
Form 4 Compass Therapeutics, Inc. For: 25 September By Investing.com - Investing.com Nigeria
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares - Investing.com
Form 4 Compass Therapeutics, Inc. For: 25 September - Investing.com India
Form 4 Compass Therapeutics, Inc. For: 25 September By Investing.com - Investing.com UK
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares By Investing.com - Investing.com Canada
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position - Stock Titan
How Does FDA Feedback Change the Tovecimig Path for Compass Therapeutics (NASDAQ:CMPX)? - Kalkine Media
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug - tradingview.com
Why Did Compass Therapeutics Stock Plunge Today?Compass Therapeutics (NASDAQ:CMPX) - Benzinga
Form 8K Compass Therapeutics, Inc. For: 22 September By Investing.com - Investing.com India
Compass Therapeutics (Nasdaq:CMPX)Stock Analysis - simplywall.st
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Compass (CMPX) Earnings Update: The EPS Result Is Below Expectation in the Current Update; After Earnings: Shares Finish 0.21% Higher on the DayProfit Cycle Analysis - vinanet.vn
Compass (CMPX) Session: Finishes 4.23% Lower at $2.38; Technical Setup: the Supplied Trading Band Runs From $2.26 to $2.50 in the Current UpdateDollar Neutral Pair - vinanet.vn
NEXTBio Capital Management LP's Compass Therapeutics Inc(CMPX) Holding History - GuruFocus
Compass (CMPX) Earnings Data Review: The EPS Result Is Below Expectation in the Available Record; Investor Response: Shares Close 3.46% Higher in the Latest SessionCore Business Growth - vinanet.vn
Compass Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate - Moomoo
Compass Therapeutics (CMPX) Climbs 3.26% to $2.22, Approaches Key ResistanceCovered Call Trade - vinanet.vn
HC Wainwright Issues Pessimistic Estimate for CMPX Earnings - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Compass Therapeutics Inc. (CMPX) Stock News Today - TradingKey
Compass Therapeutics Inc. (CMPX) Stock News Today - TradingKey
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $7 - Moomoo
Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00 at Piper Sandler - MarketBeat
Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
State Street (CMPX holder) reports 9.95M Compass Therapeutics shares on Schedule 13G - Stock Titan
Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside - TradingView
Compass Therapeutics, Inc. Q2 2026 Financial Results: Balance Sheet, Losses & Key Highlights from CMPX 10-Q Filing - Minichart
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com - Investing.com Nigeria
Compass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary - tradingview.com
Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains - stocktitan.net
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com - Investing.com Canada
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer |
Sep 24 '26 |
Buy |
1.14 |
2,500 |
2,850 |
400,000 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):